The Summary
This double-blind randomized clinical trial evaluated oral semaglutide's effects on alcohol craving and consumption. Fifty adults with moderate-to-severe alcohol use disorder (AUD) received either daily semaglutide or a placebo for eight weeks. While semaglutide did not significantly reduce laboratory-induced cravings or total daily drinks compared to placebo, it significantly decreased heavy drinking days, drinks per drinking day, real-world cravings, and alcohol-related negative consequences. Additionally, the semaglutide group experienced a notable reduction in cannabis use days and improved their risk-drinking level, suggesting strong therapeutic potential.
Why this is interesting
While semaglutide is famous for metabolic health, its potential to treat addiction is a major scientific breakthrough. Previously, evidence that GLP-1 receptor agonists reduce alcohol intake was mostly preclinical. This trial provides crucial clinical evidence that oral semaglutide can actively help treatment-seeking adults with moderate-to-severe alcohol use disorder curb heavy drinking behaviors. For readers, this suggests that future addiction treatments could leverage these same hunger-suppressing pathways to help quiet substance cravings, opening up an entirely new avenue for recovery medicine.